Ro (Roman)

Ro (Roman) Valuation and Overview

Ro (Roman)

Sectors

Health

Headquarters

625 6th Ave, New York, New York, 10011, United States

CEO

Zachariah Reitano

Ro (Roman) raised $150.0M in a Series D-1 at a $15.32728 price per share, amounting to a post-money valuation of $7.0B on January 13, 2022. PM Insights data indicates that Ro (Roman)'s shares have been trading at an 84.6% discount to their Series D-1 Valuation based on institutional secondary market activity.

Register today to view the full report, with more in-depth details and analytics

Series D-1 Valuation

Latest funding round

$7.0B

XXXXX

2022-01-13

XX-XX-XXXX

AV Implied Valuation

$1.08B

2025-02-24

AV Implied Valuation

XXXXX

XX-XX-XXXX

Change since Last Round

-84.60%

2022-01-13 ➞ 2025-02-24

Change since Last Round

XXXXX

XX-XX-XXXX

Secondary Activity

Low

XXXXX

Volume

XXX

(90 day period)

Bid

XXX

Ask

XXX

Bid

Ask

Ro (Roman) Research

Ro Revenue, Growth and Comps

Ro (Roman) News

February 12, 2025

Interested in GLP-1s for weight loss? Try Ro’s free tool to learn about options

Ro offers a free GLP-1 Insurance Checker Tool to help patients navigate insurance coverage for weight loss medications like Ozempic and Wegovy.

February 10, 2025

Best Places to Get Ozempic Online

Ro offers a streamlined enrollment process for weight loss medications like Ozempic, with insurance assistance and quick virtual consultations.

Health News Florida

January 31, 2025

Telehealth companies boost ad spending while taking on more complex medicine

Ro is leveraging high-profile advertising and expanding into complex medicine while facing scrutiny over the quality of telehealth services provided.

Register today to view the full report, with more in-depth details and analytics:

Access the full report

Register today to view the full Ro (Roman) report, with more in-depth details and analytics:

Access the full Ro (Roman) report

Ready to see it in action?

Schedule a demo with one of our experts